Neutralization of nerve growth factor (NGF) inhibits the Th2 response and protects against the respiratory syncytial virus (RSV) infection

Immunol Res. 2017 Jun;65(3):721-728. doi: 10.1007/s12026-017-8909-z.

Abstract

Increasing evidence suggests that respiratory syncytial virus (RSV) infection during the early life is an important risk factor for the development of asthma. RSV infection is associated with neurogenic inflammation in the airways along with the increased expression of nerve growth factor (NGF). However, the role of NGF in RSV infection is not clear. In this study, we infected the rat with RSV and treated these animals with anti-NGF neutralization antibody. We found that anti-NGF treatment significantly alleviated the lung inflammation as evidenced by decreased inflammatory infiltration and decreased airway resistance. Importantly, anti-NGF treatment resulted in increased Th1, but decreased Th2 immune responses, and facilitated the viral control in the tissues and blood. Therefore, NGF inhibited Th2 but increased Th1 responses in RSV infection. Pharmacological intervention of NGF signaling during severe RSV infections could prevent or decrease further asthma symptoms.

Keywords: Bronchial asthma; Nerve growth factor; Respiratory syncytial virus; Th1/Th2.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antibodies, Neutralizing / therapeutic use*
  • Asthma / prevention & control
  • Cell Movement
  • Cells, Cultured
  • Humans
  • Male
  • Nerve Growth Factor / immunology*
  • Neurogenic Inflammation
  • Pneumonia / immunology*
  • Pneumonia / therapy
  • Rats
  • Rats, Sprague-Dawley
  • Respiratory Syncytial Virus Infections / immunology*
  • Respiratory Syncytial Virus Infections / therapy
  • Respiratory Syncytial Viruses / physiology*
  • Th1 Cells / immunology*
  • Th1-Th2 Balance
  • Th2 Cells / immunology*
  • Viral Load

Substances

  • Antibodies, Neutralizing
  • Nerve Growth Factor